348 related articles for article (PubMed ID: 31831640)
1. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
2. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
4. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
[TBL] [Abstract][Full Text] [Related]
5. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.
Larrea MD; Liang J; Da Silva T; Hong F; Shao SH; Han K; Dumont D; Slingerland JM
Mol Cell Biol; 2008 Oct; 28(20):6462-72. PubMed ID: 18710949
[TBL] [Abstract][Full Text] [Related]
7. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Pack LR; Daigh LH; Chung M; Meyer T
Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
9. p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes.
Ray A; James MK; Larochelle S; Fisher RP; Blain SW
Mol Cell Biol; 2009 Feb; 29(4):986-99. PubMed ID: 19075005
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
12. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
15. Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.
Ou L; Ferreira AM; Otieno S; Xiao L; Bashford D; Kriwacki RW
J Biol Chem; 2011 Aug; 286(34):30142-51. PubMed ID: 21715330
[TBL] [Abstract][Full Text] [Related]
16. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
17. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
18. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
